ERA 2025 Archives - Medical Conferences

Home > Nephrology > ERA 2025

European Renal Association
04–07 June 2025
Vienna, Austria

Nefecon maintains kidney function regardless of baseline status over 24 months in IgA nephropathy

Presented By

Prof. Jonathan Barratt, University of Leicester, UK

Trial

Phase 3, NefIgArd

Conference

ERA 2025

Type

News article

11 June 2025 09:59

Survival benefit from kidney transplantation depends on the donor source

Presented By

Prof. Rachel Hellemans, Antwerp University Hospital, Belgium

Conference

ERA 2025

Type

News article

6 June 2025 10:49

Online First

Lumasiran shows continued promise in infants and young children with primary hyperoxaluria type 1

Presented By

Dr Wesley Hayes, Great Ormond Street Hospital for Children NHS, UK

Trial

Phase 3, ILLUMINATE-B

Conference

ERA 2025

Type

News article

11 June 2025 10:05

Ravulizumab improves long-term quality-of-life in atypical haemolytic uraemic syndrome

Trial

Phase 3

Conference

ERA 2025

Type

News article

11 June 2025 10:03

Anti-PAPP-A antibody shows preclinical promise for autosomal dominant polycystic kidney disease

Presented By

Dr Georgios Koukos, Calico Life Sciences, CA, USA

Conference

ERA 2025

Type

News article

11 June 2025 10:01

Nefecon maintains kidney function regardless of baseline status over 24 months in IgA nephropathy

Presented By

Prof. Jonathan Barratt, University of Leicester, UK

Trial

Phase 3, NefIgArd

Conference

ERA 2025

Type

News article

11 June 2025 09:59

Iptacopan improves mesenchymal and capillary glomerular C3 deposition in patients with C3 glomerulopathy

Trial

Phase 3, APPEAR-C3G

Conference

ERA 2025

Type

News article

11 June 2025 09:57

Sibeprenlimab is an emerging treatment option for IgA nephropathy

Presented By

Prof. Vlado Perkovic, University of New South Wales, Australia

Trial

Phase 3, VISIONARY

Conference

ERA 2025

Type

News article

10 June 2025 10:41

Pegcetacoplan is treatment option for adolescents with C3G or IC-MPGN

Presented By

Dr Antonio Mastrangelo, Policlinico of Milan, Italy

Trial

Phase 3, VALIANT

Conference

ERA 2025

Type

News article

10 June 2025 10:39

Mineral receptor antagonists not beneficial for patients undergoing dialysis

Presented By

Dr Lonnie Pyne, McMaster University, Canada

Conference

ERA 2025

Type

News article

10 June 2025 10:38

Spironolactone not useful in dialysis with cardiovascular risk

Presented By

Dr Michael Walsh, McMaster University, Canada

Trial

Phase 3, ACHIEVE

Conference

ERA 2025

Type

News article

10 June 2025 10:36

Acute eGFR dip following empagliflozin initiation not associated with acute kidney injury

Presented By

Dr Natalie Staplin, University of Oxford, UK

Conference

ERA 2025

Type

News article

10 June 2025 10:34

Survival benefit from kidney transplantation depends on the donor source

Presented By

Prof. Rachel Hellemans, Antwerp University Hospital, Belgium

Conference

ERA 2025

Type

News article

6 June 2025 10:49

Canagliflozin has dose-dependent effect on cardiovascular outcomes in patients with type 2 diabetes

Presented By

Dr Elias Elenjickal, McGill University Health Centre, Canada

Trial

CANVAS

Conference

ERA 2025

Type

News article

6 June 2025 10:46

Large meta-analysis shows empagliflozin slows kidney progression and reduces risk among patients with multiple diseases

Presented By

Prof. William Herrington, University of Oxford, UK

Conference

ERA 2025

Type

News article

6 June 2025 10:43

Factor XI inhibition not useful for end-stage kidney disease patients receiving haemodialysis

Presented By

Prof. Wolfgang Winkelmayer, Baylor College of Medicine, TX, USA

Trial

Phase 2

Conference

ERA 2025

Type

News article

6 June 2025 10:41

Finerenone plus empagliflozin as new potential combination in patients with type 2 diabetes and chronic kidney disease

Presented By

Prof. Johannes Mann, Friedrich Alexander University, Germany

Trial

Phase 2, CONFIDENCE

Conference

ERA 2025

Type

News article

6 June 2025 10:40

Medical Conferences

ERA 2025

Featured articles

Nefecon maintains kidney function regardless of baseline status over 24 months in IgA nephropathy

Survival benefit from kidney transplantation depends on the donor source

CONTENTS

Online First

Lumasiran shows continued promise in infants and young children with primary hyperoxaluria type 1

Ravulizumab improves long-term quality-of-life in atypical haemolytic uraemic syndrome

Anti-PAPP-A antibody shows preclinical promise for autosomal dominant polycystic kidney disease

Nefecon maintains kidney function regardless of baseline status over 24 months in IgA nephropathy

Iptacopan improves mesenchymal and capillary glomerular C3 deposition in patients with C3 glomerulopathy

Sibeprenlimab is an emerging treatment option for IgA nephropathy

Pegcetacoplan is treatment option for adolescents with C3G or IC-MPGN

Mineral receptor antagonists not beneficial for patients undergoing dialysis

Spironolactone not useful in dialysis with cardiovascular risk

Acute eGFR dip following empagliflozin initiation not associated with acute kidney injury

Survival benefit from kidney transplantation depends on the donor source

Canagliflozin has dose-dependent effect on cardiovascular outcomes in patients with type 2 diabetes

Large meta-analysis shows empagliflozin slows kidney progression and reduces risk among patients with multiple diseases

Factor XI inhibition not useful for end-stage kidney disease patients receiving haemodialysis

Finerenone plus empagliflozin as new potential combination in patients with type 2 diabetes and chronic kidney disease